Competition Coming For Hemophilia Franchises, But Will Patients And Payers Embrace New Drugs?
Executive Summary
Roche's emicizumab, Alnylam's fitusiran and multiple gene therapies may soon steal market share from established clotting factors sold by Shire, Novo Nordisk and others, but safety is a key consideration for physicians and patients.